<DOC>
	<DOC>NCT01417377</DOC>
	<brief_summary>This observational, prospective, multi-centre, single-arm study will evaluate the efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in patients with chronic kidney disease previously on treatment with short-acting epoetin alpha. Data will be collected for 6 months.</brief_summary>
	<brief_title>An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Anemic Patients With Chronic Kidney Disease (NORM)</brief_title>
	<detailed_description />
	<criteria>Adult patients, age 18 years or above Chronic kidney disease (CKD) with anemia Patients on dialysis receiving shortacting epoetin (EPO) Serum ferritin level &gt;/=100 ng/ml or transferrin saturation (TSAT) &gt;/=20% Patients unwilling to give informed consent Uncontrolled hypertension Transfusion of red blood cells within 8 weeks of the start of Mircera treatment Relevant acute or chronic bleeding history Hemolysis Hemoglobinopathies Pure red cell aplasia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>